Signal active
Contact Information
Social
Primary Organization
2017
11-50
Biotechnology, Health Care, Therapeutics
Bio
Michael Saunders has been discovering novel drugs and selecting therapeutic targets for 25 years, and joined argenx in 2009. At argenx he has been responsible for External Research and the Innovative Access Program, Target Selection, has contributed to the discovery of six antibodies in clinical and preclinical development, and is responsible for academic collaborations and Alliance Management with Pharma partners. He has written and obtained 5 Research Grants (>12M€). Previously, Michael Saunders working for Ablynx NV as an independent senior interim project director leading the successful Nanobody Landgrab program selecting 100 therapeutic targets, and resulting in the identification of Nanobodies of therapeutic relevance against these targets, 20 patent applications, 4 internal drug development programs and 5 scientific publications. Previously he worked at Devgen and GSK. Michael Saunders holds at MA from Cambridge University (UK), a PhD in Biology from the University North Carolina (USA) and an eMBA from ESSEC (France) and Mannheim (Germany) business schools.
Location
Brussels, Brussels Hoofdstedelijk Gewest, Belgium, Europe
Jobs history
1
AgomAb Therapeutics
Co-founder
Invalid date - Current
Educations
1
N/A
Profile Resume
Michael Saunders is the Co-founder at AgomAb Therapeutics, based in Europe. With a background in Biotechnology, Michael Saunders has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Products and Innovations
0
There is no product and inovations for this profile.
Achievements
0
There is no Achievements for this profile.
Publications
0
There is no publication for this profile.
Recent Activity
There is no recent news or activity for this profile.